Molecular docking of potential inhibitors with the mTOR protein

The mTOR (mammalian or mechanistic Target of Rapamycin) is linked with oral cancer. Therefore, it is of interest to study the molecular docking-based binding of paclitaxel (a FDA approved drug for oral cancer) and its analogues with mTOR. Hence, we report the binding features of 10-Deacetyltaxol, 7-...

Full description

Saved in:
Bibliographic Details
Published in:Bioinformation 2021-01, Vol.17 (1), p.212-217
Main Authors: Fathima, Jh Shazia, Selvaraj, Jayaraman, Sivabalan, Venkatacalam, Rekha, Umapathy Vidhya, Ponnulakshmi, Rajagopal, Vishnupriya, Veeraraghavan, Kullappan, Malathi, Sreekandan, Radhika Nalinakumari, Mohan, Surapaneni Krishna, Vijayalakshmi, Periyasamy
Format: Article
Language:English
Subjects:
Binding
Cancer
Molecular docking
Oral cancer
Paclitaxel
Rapamycin
TOR protein
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The mTOR (mammalian or mechanistic Target of Rapamycin) is linked with oral cancer. Therefore, it is of interest to study the molecular docking-based binding of paclitaxel (a FDA approved drug for oral cancer) and its analogues with mTOR. Hence, we report the binding features of 10-Deacetyltaxol, 7-Epi-10-deacetyltaxol, 7-Epi-Taxol and 6alpha-Hydroxypaclitaxel with mTOR for further consideration.
ISSN:0973-2063
0973-8894
0973-2063
DOI:10.6026/97320630017212